Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.
Enxing Seng, 47, will lead the division’s 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm’s respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.
Enxing Seng was a founding member of ev3 and led its peripheral vascular division, according to a press release.
Sign up to get our free newsletters delivered right to your inbox
Last week, Covidien made CEO Joe Almeida chairman of the board and tapped former Bayer Healthcare chief Mark Trudeau to lead its pharmaceuticals division ahead of a planned spinout.
Aethlon Medical sets up advisory board
Aethlon Medical (OTC:AEMD) established an extracorporeal therapy scientific advisory board "to guide the advancement of the Aethlon Hemopurifier and other therapies developed from the Aethlon ADAPT system," saying it plans to add other advisory boards this year. Read more
AtriCure hires Lux to be COO
AtriCure (NSDQ:ATRC) named Andrew Lux to be its COO effective Jan. 16. Read more
Sirona Dental loses 2 board members
Sirona Dental Systems (NSDQ:SIRO) said 2 of its board members, Nicholas Alexos and Timothy Sheehan, are stepping down. Read more
The post Covidien names new vascular leader | Personnel Moves appeared first on MassDevice.